Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies
Journal article
NIKOLAOU N. et al, (2021), The Journal of Steroid Biochemistry and Molecular Biology, 105808 - 105808
-
Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance.
Journal article
Geberhiwot T. et al, (2020), Diabetes
-
The ALIOS diet in male and female rodents recapitulates the clinical and transcriptomic features of NAFLD and NASH.
Journal article
Harris SE. et al, (2020), Am J Physiol Gastrointest Liver Physiol
-
Fighting liver fat.
Journal article
Koeckerling D. et al, (2020), Endocr Connect
-
Guidance for the prevention and emergency management of adult patients with adrenal insufficiency
Journal article
Simpson H. et al, (2020), Clinical medicine (London, England), 20, 371 - 378